Tourmaline Bio, Inc. presented data from the Phase 2 TRANQUILITY trial of pacibekitug at the ESC Congress 2025, showcasing reductions in high-sensitivity C-reactive protein (hs-CRP) across various subgroups. Dr. Deepak L. Bhatt emphasized the consistent reductions in hs-CRP and other key biomarkers like lipoprotein(a) and fibrinogen. Pacibekitug demonstrated deep and durable reductions in hs-CRP with statistical significance compared to placebo. These results support further evaluation in atherosclerotic cardiovascular disease. Pacibekitug also showed reductions in IL-6 pathway biomarkers, making it the first IL-6 inhibitor to achieve deep hs-CRP reductions with quarterly dosing.

Read more at GlobeNewswire: Tourmaline Bio Presents Data from the Ongoing Phase 2